Overview
ARVN market data
Price History
ARVN price chart · 1M
- O
- 7.08
- H
- 7.29
- L
- 7.01
- C
- 7.03
- Vol
- 41,295.00
Daily history from Sep 27, 2018
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $7.08
- Previous Close
- $7.16
- Day High
- $7.29
- Day Low
- $7.01
- 52 Week High
- $14.28
- 52 Week Low
- $6.75
- 7 Day Return
- -8.17%
- 30 Day Return
- -13.91%
- 90 Day Return
- -12.30%
- 1 Year Return
- -27.35%
- Daily Notional Volume
- $290.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 47.84 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.14 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.80 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.80 – $14.51 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $445M · P/B 1.76 · P/S 1.41.
Company News
10 captured
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s DiseaseGlobenewswire Inc ·
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology CandidateGlobenewswire Inc ·
Arvinas Announces First Patient Dosed In Phase 1/2 Trial Of ARV-6723 In Advanced Solid TumorsBenzinga ·
Arvinas Q2 2026 Earnings Call TranscriptBenzinga ·